Benefits Seen With Apalutamide Plus ADT in Metastatic Castration-Sensitive Prostate Cancer

Date Posted: 
2019-06-03
Dr. Chi

The TITAN clinical trial has demonstrated that the addition of apalutamide to androgen-deprivation therapy significantly improved radiographic progression-free survival and overall survival in patients with metastatic castration-sensitive prostate cancer. These results were presented by Dr. Kim Chi at ASCO on May 31, and were written up on ASCO Daily News on June 1.  Dr. Chi is first author on the study which was published in the New England Journal of Medicine on May 31.

 

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Rock4Prostate

Rock4Prostate fundraiser - Friday Nov 8, 2019

The 2nd annual Rock4Prostate event takes place Friday Nov 8 at the Backstage Lounge Pub on Granville Island.  Tickets available at Eventbrite and at the door ($20 or $10 for students 19+), with proceeds going to Prostate Cancer Canada.  Please visit the Facebook event page for more details

VPC Movember 2013 team

Movember fundraiser: Nov. 1 - 30, 2019

Movember is an international charity raising funds for men's health initiatives. Movember Canada focuses on prostate cancer, testicular cancer, mental health and suicide prevention. Please visit moteam.co/the-vancouver-prostate-centre to join or donate to our Centre's Movember fundraising team.

Employment

Work at the Vancouver Prostate Centre

Tuesday, December 3, 2019

Dr. Jefferies elected as a Fellow of the National Academy of Inventors

Dr. Jefferies
Tuesday, November 19, 2019

Dr. Lallous appointed Senior Research Scientist, featured in VCH News

Dr. Lallous